Evidence map›Paper›PMID 41087181›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Clinical characteristics and survival outcomes of patients with immunoglobulin A multiple myeloma in the bortezomib era: A single-center retrospective cohort study].

F Gao, H Wang, Y L Zhou, S X Wang, M Yu, F Li

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

F GaoDepartment of Hematology, The First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Jiangxi Provincial Key Laboratory of Hematological Diseases, Nanchang 330006, China.
H WangDepartment of Hematology, The First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Jiangxi Provincial Key Laboratory of Hematological Diseases, Nanchang 330006, China.
Y L ZhouDepartment of Hematology, The First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Jiangxi Provincial Key Laboratory of Hematological Diseases, Nanchang 330006, China.
S X WangDepartment of Hematology, The First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Jiangxi Provincial Key Laboratory of Hematological Diseases, Nanchang 330006, China.
M YuDepartment of Hematology, The First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Jiangxi Provincial Key Laboratory of Hematological Diseases, Nanchang 330006, China.
F LiDepartment of Hematology, The First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Jiangxi Provincial Key Laboratory of Hematological Diseases, Nanchang 330006, China.

Funding

Science and Technology Innovation Base Construction Project of Jiangxi Province 20212BCG74001the Jiangxi Provincial Key Laboratory of Hematological Diseases 2024SSY06051the Program for Academic and Technical Leaders of Jiangxi Province 20213BCJ22016
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BortezomibImmunoglobulin AMultiple MyelomaAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeBortezomibImmunoglobulin AClinical featuresEfficacyIgA typeMultiple myelomaPrognostic analysis

Identifiers

PMID41087181
PMCPMC12541474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.